Skip to main content
. 2022 Feb 15;31(15):2498–2507. doi: 10.1093/hmg/ddab363

Figure 6.

Figure 6

Tau oligomer pathology in differentiated AD and MCI trans-mitochondrial cybrid cells and human platelets. (A, B) The bar graph presents quantification of immunodot blotting for TOC1 normalized to β-actin on differentiated MCI and AD trans-mitochondrial cybrid cells (A) and human platelets (B). n = 5 for cybrids and 7 for platelets per group. The representative immunodot blottings were shown for TOC1 from indicated cybrids (A) and platelets (B), and β-actin served as a loading control. (C) The bar graph presents quantification of immunodot blotting for TOC1 normalized to β-actin on differentiated MCI and AD trans-mitochondrial cybrid cells with or without mito-TEMPO treatment. The representative immunodot blottings were shown for TOC1 from indicated cybrids and β-actin served as a loading control.